jVen Capital

Established in 2007, jVen Capital is a privately held life sciences investment management company specializing in venture capital and growth equity investments. The firm concentrates on personalized medicine, genetics, and medical devices, aiming to enhance science through hands-on management and rigorous execution of comprehensive business plans.

Founded by Evan Jones, a successful entrepreneur in the life sciences and molecular diagnostics fields, jVen Capital works closely with its portfolio companies to develop their visions and build successful businesses. Prior to forming jVen Capital, Mr. Jones co-founded, served as Chairman, and was CEO of Digene Corporation, a publicly traded biotechnology company focused on women's health and molecular diagnostic testing.

jVen Capital has invested in more than a dozen life sciences transactions, including active investments in Veracyte, Sunwink, GeneWerk Holdings GmbH, and Kyverna Therapeutics. Past successful investments include Fluidigm, Assurex Health, CAS Medical Systems, superDimension, Digene Corp, Signature Genomic Laboratories, Foundation Medicine, and OpGen. The firm is committed to thoughtfully and patiently building sustainable, market-leading businesses in the life sciences sector.